TCGA-49-AAR3-01A-11R-A41B-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.590
- INTERFERON_GAMMA_RESPONSE+0.570
- ALLOGRAFT_REJECTION+0.550
- INFLAMMATORY_RESPONSE+0.500
- IL6_JAK_STAT3_SIGNALING+0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.460
- COMPLEMENT+0.410
- ANGIOGENESIS+0.380
- KRAS_SIGNALING_UP+0.340
- COAGULATION+0.330
Top 10 suppressed
- PROTEIN_SECRETION-0.530
- OXIDATIVE_PHOSPHORYLATION-0.510
- UNFOLDED_PROTEIN_RESPONSE-0.460
- MYC_TARGETS_V1-0.450
- PEROXISOME-0.420
- ADIPOGENESIS-0.390
- ANDROGEN_RESPONSE-0.370
- CHOLESTEROL_HOMEOSTASIS-0.370
- FATTY_ACID_METABOLISM-0.350
- DNA_REPAIR-0.330
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR607445 | GTEX | — | 0.904 |
| 2 | TCGA-95-7944-01A-11R-2187-07 | — | cohortA1 | 0.894 |
| 3 | SRR1335446 | GTEX | — | 0.890 |
| 4 | MNG1166 | — | — | 0.881 |
| 5 | SRR603658 | GTEX | — | 0.880 |
| 6 | SRR1358561 | GTEX | — | 0.879 |
| 7 | MNG303 | — | — | 0.878 |
| 8 | DRR168543 | — | — | 0.876 |
| 9 | 767fc312-2c66-43f7-b78e-bf79e03e3a0a | — | — | 0.871 |
| 10 | f98f9a57-095b-482a-893c-030f9ad9db02 | — | — | 0.871 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 20 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.590 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.550 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.470 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.460 | Inavolisib | — uncovered |
| COMPLEMENT | 0.410 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.380 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| APOPTOSIS | 0.090 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.030 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.030 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.020 | Inavolisib | — uncovered |